{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T20:23:41Z","timestamp":1769718221939,"version":"3.49.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T00:00:00Z","timestamp":1762646400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T00:00:00Z","timestamp":1762646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s10067-025-07743-y","type":"journal-article","created":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T02:43:26Z","timestamp":1762656206000},"page":"365-373","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pre-existing diabetes mellitus and PR3-ANCA positivity as predictors of relapse in ANCA-associated vasculitis: a retrospective cohort study"],"prefix":"10.1007","volume":"45","author":[{"given":"Akifumi","family":"Tabei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7031-0651","authenticated-orcid":false,"given":"Yoichi","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Sakairi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Ohishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuharu","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masao","family":"Nakasatomi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroko","family":"Hamatani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidekazu","family":"Ikeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoriaki","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiju","family":"Hiromura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,9]]},"reference":[{"issue":"4","key":"7743_CR1","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S0272-6386(03)00025-8","volume":"41","author":"AD Booth","year":"2003","unstructured":"Booth AD, Almond MK, Burns A, Ellis P, Gaskin G, Neild GH et al (2003) Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis 41(4):776\u2013784","journal-title":"Am J Kidney Dis"},{"issue":"10","key":"7743_CR2","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1093\/ndt\/16.10.2018","volume":"16","author":"K de Groot","year":"2001","unstructured":"de Groot K, Adu D, Savage CO (2001) The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol Dial Transplant 16(10):2018\u20132027","journal-title":"Nephrol Dial Transplant"},{"issue":"9","key":"7743_CR3","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1002\/art.23800","volume":"58","author":"C Pagnoux","year":"2008","unstructured":"Pagnoux C, Hogan SL, Chin H, Jennette JC, Falk RJ, Guillevin L et al (2008) Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts. Arthritis Rheum 58(9):2908\u20132918","journal-title":"Arthritis Rheum"},{"issue":"1","key":"7743_CR4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1681\/ASN.V7133","volume":"7","author":"PH Nachman","year":"1996","unstructured":"Nachman PH, Hogan SL, Jennette JC, Falk RJ (1996) Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 7(1):33\u201339","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"7743_CR5","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa041884","volume":"352","author":"T Wegener","year":"2005","unstructured":"Wegener T, Trial GE (2005) Etanercept plus standard therapy for Wegener\u2019s granulomatosis. N Engl J Med. 352(4):351\u201361","journal-title":"N Engl J Med."},{"issue":"3","key":"7743_CR6","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/art.10459","volume":"47","author":"E Reinhold-Keller","year":"2002","unstructured":"Reinhold-Keller E, Fink CO, Herlyn K, Gross WL, De Groot K (2002) High rate of renal relapse in 71 patients with Wegener\u2019s granulomatosis under maintenance of remission with low-dose methotrexate. Arthritis Rheum 47(3):326\u2013332","journal-title":"Arthritis Rheum"},{"issue":"4","key":"7743_CR7","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1056\/NEJMp048338","volume":"352","author":"PA Bacon","year":"2005","unstructured":"Bacon PA (2005) The spectrum of Wegener\u2019s granulomatosis and disease relapse. N Engl J Med 352(4):330\u2013332","journal-title":"N Engl J Med"},{"issue":"3","key":"7743_CR8","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3109\/s10165-011-0525-5","volume":"22","author":"S Ozaki","year":"2012","unstructured":"Ozaki S, Atsumi T, Hayashi T, Ishizu A, Kobayashi S, Kumagai S et al (2012) Severity-based treatment for Japanese patients with MPO-ANCA-associated vasculitis: the JMAAV study. Mod Rheumatol 22(3):394\u2013404","journal-title":"Mod Rheumatol"},{"issue":"9","key":"7743_CR9","doi-asserted-by":"publisher","first-page":"621","DOI":"10.7326\/0003-4819-143-9-200511010-00005","volume":"143","author":"SL Hogan","year":"2005","unstructured":"Hogan SL, Falk RJ, Chin H, Cai J, Jennette CE, Jennette JC et al (2005) Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med 143(9):621\u2013631","journal-title":"Ann Intern Med"},{"issue":"7","key":"7743_CR10","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1002\/art.38621","volume":"66","author":"ZY Li","year":"2014","unstructured":"Li ZY, Chang DY, Zhao MH, Chen M (2014) Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated vasculitis: a study of 439 cases in a single Chinese center. Arthritis Rheumatol 66(7):1920\u20131926","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"7743_CR11","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1002\/art.21142","volume":"52","author":"K De Groot","year":"2005","unstructured":"De Groot K, Rasmussen N, Bacon PA, Tervaert JW, Feighery C, Gregorini G et al (2005) Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52(8):2461\u20132469","journal-title":"Arthritis Rheum"},{"issue":"1","key":"7743_CR12","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa020286","volume":"349","author":"D Jayne","year":"2003","unstructured":"Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadonien\u00e9 J et al (2003) A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 349(1):36\u201344","journal-title":"N Engl J Med"},{"issue":"10","key":"7743_CR13","doi-asserted-by":"publisher","first-page":"670","DOI":"10.7326\/0003-4819-150-10-200905190-00004","volume":"150","author":"K de Groot","year":"2009","unstructured":"de Groot K, Harper L, Jayne DR, Flores Suarez LF, Gregorini G, Gross WL et al (2009) Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 150(10):670\u2013680","journal-title":"Ann Intern Med"},{"issue":"7","key":"7743_CR14","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1681\/ASN.2007010090","volume":"18","author":"DR Jayne","year":"2007","unstructured":"Jayne DR, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L et al (2007) Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 18(7):2180\u20132188","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"7743_CR15","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/art.33361","volume":"64","author":"M Walsh","year":"2012","unstructured":"Walsh M, Flossmann O, Berden A, Westman K, H\u00f6glund P, Stegeman C et al (2012) Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 64(2):542\u2013548","journal-title":"Arthritis Rheum"},{"issue":"3","key":"7743_CR16","doi-asserted-by":"publisher","DOI":"10.1093\/rap\/rkab018","volume":"5","author":"C King","year":"2021","unstructured":"King C, Druce KL, Nightingale P, Kay E, Basu N, Salama AD et al (2021) Predicting relapse in anti-neutrophil cytoplasmic antibody-associated vasculitis: a systematic review and meta-analysis. Rheumatol Adv Pract 5(3):rkab018","journal-title":"Rheumatol Adv Pract"},{"issue":"1","key":"7743_CR17","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1080\/14397595.2016.1192760","volume":"27","author":"T Murosaki","year":"2017","unstructured":"Murosaki T, Sato T, Akiyama Y, Nagatani K, Minota S (2017) Difference in relapse-rate and clinical phenotype by autoantibody-subtype in Japanese patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. Mod Rheumatol 27(1):95\u2013101","journal-title":"Mod Rheumatol"},{"issue":"4","key":"7743_CR18","doi-asserted-by":"publisher","first-page":"521","DOI":"10.3899\/jrheum.170508","volume":"45","author":"A Hara","year":"2018","unstructured":"Hara A, Wada T, Sada KE, Amano K, Dobashi H, Harigai M et al (2018) Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis in Japan: a nationwide, prospective cohort study. J Rheumatol 45(4):521\u2013528","journal-title":"J Rheumatol"},{"issue":"2","key":"7743_CR19","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1136\/ard.2006.054593","volume":"66","author":"R Watts","year":"2007","unstructured":"Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W et al (2007) Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 66(2):222\u2013227","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"7743_CR20","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1136\/ard.2008.101279","volume":"68","author":"C Mukhtyar","year":"2009","unstructured":"Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B, Dubey S et al (2009) Modification and validation of the Birmingham vasculitis activity score (version 3). Ann Rheum Dis 68(12):1827\u20131832","journal-title":"Ann Rheum Dis"},{"issue":"1\u20132","key":"7743_CR21","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/0022-1759(96)00123-8","volume":"197","author":"MH Zhao","year":"1996","unstructured":"Zhao MH, Lockwood CM (1996) A comprehensive method to purify three major ANCA antigens: proteinase 3, myeloperoxidase and bactericidal\/permeability-increasing protein from human neutrophil granule acid extract. J Immunol Methods 197(1\u20132):121\u2013130","journal-title":"J Immunol Methods"},{"issue":"5","key":"7743_CR22","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1136\/ard.2006.062711","volume":"66","author":"B Hellmich","year":"2007","unstructured":"Hellmich B, Flossmann O, Gross WL, Bacon P, Cohen-Tervaert JW, Guillevin L et al (2007) EULAR recommendations for conducting clinical studies and\/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 66(5):605\u2013617","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"7743_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0218705","volume":"14","author":"M Morishita","year":"2019","unstructured":"Morishita M, Sada KE, Matsumoto Y, Hayashi K, Asano Y, Hiramatsu Asano S et al (2019) Risk factors for cytomegalovirus infection in patients with antineutrophil cytoplasmic antibody-associated vasculitis. PLoS ONE 14(7):e0218705","journal-title":"PLoS ONE"},{"issue":"5663","key":"7743_CR24","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1126\/science.1092385","volume":"303","author":"V Brinkmann","year":"2004","unstructured":"Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS et al (2004) Neutrophil extracellular traps kill bacteria. Science 303(5663):1532\u20131535","journal-title":"Science"},{"issue":"6","key":"7743_CR25","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/nm.1959","volume":"15","author":"K Kessenbrock","year":"2009","unstructured":"Kessenbrock K, Krumbholz M, Sch\u00f6nermarck U, Back W, Gross WL, Werb Z et al (2009) Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med 15(6):623\u2013625","journal-title":"Nat Med"},{"issue":"3","key":"7743_CR26","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s00592-014-0676-x","volume":"52","author":"L Menegazzo","year":"2015","unstructured":"Menegazzo L, Ciciliot S, Poncina N, Mazzucato M, Persano M, Bonora B et al (2015) NETosis is induced by high glucose and associated with type 2 diabetes. Acta Diabetol 52(3):497\u2013503","journal-title":"Acta Diabetol"},{"issue":"7","key":"7743_CR27","doi-asserted-by":"publisher","first-page":"4998","DOI":"10.21037\/qims-23-1717","volume":"14","author":"ZY Li","year":"2024","unstructured":"Li ZY, Kang M, Qian XZ, Peng R, Hong Q, Ying P et al (2024) Retinal thickness and microvascular alterations observed by optical coherence tomography in antineutrophil cytoplasmic antibody-associated vasculitis: a cross-sectional study. Quant Imaging Med Surg 14(7):4998\u20135011","journal-title":"Quant Imaging Med Surg"},{"issue":"1","key":"7743_CR28","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1093\/rheumatology\/kes345","volume":"52","author":"DR Petermann Smits","year":"2013","unstructured":"Petermann Smits DR, Wilde B, Kianersi Adegani M, de Jongh H, van Paassen P, Cohen Tervaert JW (2013) Metabolic syndrome in ANCA-associated vasculitis. Rheumatology (Oxford) 52(1):197\u2013203","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"7743_CR29","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1186\/s12882-022-02913-5","volume":"23","author":"PG Park","year":"2022","unstructured":"Park PG, Pyo JY, Ahn SS, Song JJ, Park YB, Lee SW (2022) Serum glycated albumin as a predictive biomarker for renal involvement of antineutrophil cytoplasmic antibody-associated vasculitis in non-diabetic patients. BMC Nephrol 23(1):288","journal-title":"BMC Nephrol"},{"issue":"9","key":"7743_CR30","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/art.42843","volume":"76","author":"ML Junek","year":"2024","unstructured":"Junek ML, Merkel PA, Vilayur E, Wald R, Khalidi N, Jayne D et al (2024) Risk of relapse of antineutrophil cytoplasmic antibody-associated vasculitis in a randomized controlled trial of plasma exchange and glucocorticoids. Arthritis Rheumatol 76(9):1431\u20131438","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"7743_CR31","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1093\/rheumatology\/ker205","volume":"50","author":"S Fujimoto","year":"2011","unstructured":"Fujimoto S, Watts RA, Kobayashi S, Suzuki K, Jayne DR, Scott DG et al (2011) Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the U.K. Rheumatology (Oxford) 50(10):1916\u20131920","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"7743_CR32","first-page":"828","volume":"42","author":"YJ Lee","year":"2024","unstructured":"Lee YJ, Ahn SM, Oh JS, Kim YG, Lee CK, Yoo B et al (2024) Relapse in patients with antineutrophil cytoplasmic antibody-associated vasculitis undergoing dialysis: a single-centre retrospective study in South Korea. Clin Exp Rheumatol 42(4):828\u2013833","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"7743_CR33","first-page":"848","volume":"41","author":"C Jiang","year":"2023","unstructured":"Jiang C, Liu J, Wang H, Liu H, Fu Z, Li M et al (2023) Anti-neutrophil cytoplasmic antibody patterns can predict clinical relapse in ANCA-associated vasculitis: overall population and subgroups. Clin Exp Rheumatol 41(4):848\u2013855","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"7743_CR34","doi-asserted-by":"publisher","first-page":"3142","DOI":"10.1093\/rheumatology\/keae540","volume":"64","author":"S Bayati","year":"2025","unstructured":"Bayati S, Nazeer J, Ng J, George AM, Hayes M, Little MA et al (2025) Autoantibodies towards HFE and SYT5 in anti-neutrophil cytoplasm antibody-associated vasculitis relapse. Rheumatology (Oxford) 64(5):3142\u20133150","journal-title":"Rheumatology (Oxford)"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07743-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-025-07743-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07743-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T09:41:17Z","timestamp":1769679677000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-025-07743-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,9]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["7743"],"URL":"https:\/\/doi.org\/10.1007\/s10067-025-07743-y","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,9]]},"assertion":[{"value":"6 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in compliance with the Declaration of Helsinki and its subsequent amendments and was approved by the Gunma University Ethical Review Board for Medical Research Involving Human Subjects (approval date: March 17, 2021; protocol number: HS2020-246). Informed consent was waived because of the retrospective design of data collection. We provided the opportunity to opt out of the study by informing the participants through the website of our hospital and the websites or posts of the 18 medical facilities to which the patients were referred.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"KH received consultancy fees from Otsuka Pharmaceutical and GlaxoSmithKline, research support from Chugai Pharmaceutical, and speaker fees from Astellas Pharma, AstraZeneca, Asahi Kasei Pharma, GlaxoSmithKline, Kissei Pharmaceutical, and Otsuka Pharmaceutical. The other authors have disclosed no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}